Basilea Pharmaceutica AG - Product Pipeline Review - 2014

Published: Nov, 2014 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Basilea Pharmaceutica AG - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Basilea Pharmaceutica AG - Product Pipeline Review - 2014', provides an overview of the Basilea Pharmaceutica AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Basilea Pharmaceutica AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Basilea Pharmaceutica AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Basilea Pharmaceutica AG's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Basilea Pharmaceutica AG's pipeline products

Reasons to buy

- Evaluate Basilea Pharmaceutica AG's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Basilea Pharmaceutica AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Basilea Pharmaceutica AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Basilea Pharmaceutica AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Basilea Pharmaceutica AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Basilea Pharmaceutica AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Basilea Pharmaceutica AG Snapshot 5
Basilea Pharmaceutica AG Overview 5
Key Information 5
Key Facts 5
Basilea Pharmaceutica AG - Research and Development Overview 6
Key Therapeutic Areas 6
Basilea Pharmaceutica AG - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Basilea Pharmaceutica AG - Pipeline Products Glance 13
Basilea Pharmaceutica AG - Late Stage Pipeline Products 13
Pre-Registration Products/Combination Treatment Modalities 13
Filing rejected/Withdrawn Products/Combination Treatment Modalities 14
Phase III Products/Combination Treatment Modalities 15
Basilea Pharmaceutica AG - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Basilea Pharmaceutica AG - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Basilea Pharmaceutica AG - Drug Profiles 20
isavuconazonium sulfate 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
ceftobiprole medocaril 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
BAL-101553 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
BAL-30072 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecule For Inflammatory Diseases 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecules for Hematological and Solid Cancers 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecules to Inhibit Beta-Lactamase for Bacterial Infections 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Basilea Pharmaceutica AG - Pipeline Analysis 30
Basilea Pharmaceutica AG - Pipeline Products by Target 30
Basilea Pharmaceutica AG - Pipeline Products by Route of Administration 31
Basilea Pharmaceutica AG - Pipeline Products by Molecule Type 32
Basilea Pharmaceutica AG - Pipeline Products by Mechanism of Action 33
Basilea Pharmaceutica AG - Recent Pipeline Updates 34
Basilea Pharmaceutica AG - Dormant Projects 43
Basilea Pharmaceutica AG - Discontinued Pipeline Products 44
Discontinued Pipeline Product Profiles 44
BAL-2299 44
Basilea Pharmaceutica AG - Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

List of Tables
Basilea Pharmaceutica AG, Key Information 5
Basilea Pharmaceutica AG, Key Facts 5
Basilea Pharmaceutica AG - Pipeline by Indication, 2014 8
Basilea Pharmaceutica AG - Pipeline by Stage of Development, 2014 9
Basilea Pharmaceutica AG - Monotherapy Products in Pipeline, 2014 10
Basilea Pharmaceutica AG - Out-Licensed Products in Pipeline, 2014 11
Basilea Pharmaceutica AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
Basilea Pharmaceutica AG - Pre-Registration, 2014 13
Basilea Pharmaceutica AG - Filing rejected/Withdrawn, 2014 14
Basilea Pharmaceutica AG - Phase III, 2014 15
Basilea Pharmaceutica AG - Phase II, 2014 16
Basilea Pharmaceutica AG - Phase I, 2014 17
Basilea Pharmaceutica AG - Preclinical, 2014 18
Basilea Pharmaceutica AG - Discovery, 2014 19
Basilea Pharmaceutica AG - Pipeline by Target, 2014 30
Basilea Pharmaceutica AG - Pipeline by Route of Administration, 2014 31
Basilea Pharmaceutica AG - Pipeline by Molecule Type, 2014 32
Basilea Pharmaceutica AG - Pipeline Products by Mechanism of Action, 2014 33
Basilea Pharmaceutica AG - Recent Pipeline Updates, 2014 34
Basilea Pharmaceutica AG - Dormant Developmental Projects,2014 43
Basilea Pharmaceutica AG - Discontinued Pipeline Products, 2014 44
Basilea Pharmaceutica AG, Subsidiaries 45